# | Title | Journal | Year | Citations |
---|
1 | Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction | Expert Opinion on Drug Metabolism and Toxicology | 2006 | 1,122 |
2 | Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily | Expert Opinion on Drug Metabolism and Toxicology | 2008 | 646 |
3 | The Simcyp®Population-based ADME Simulator | Expert Opinion on Drug Metabolism and Toxicology | 2009 | 438 |
4 | Caco-2 cell permeability assays to measure drug absorption | Expert Opinion on Drug Metabolism and Toxicology | 2005 | 408 |
5 | The Caco-2 cell monolayer: usefulness and limitations | Expert Opinion on Drug Metabolism and Toxicology | 2008 | 367 |
6 | Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily | Expert Opinion on Drug Metabolism and Toxicology | 2008 | 312 |
7 | Antisense oligonucleotide pharmacokinetics and metabolism | Expert Opinion on Drug Metabolism and Toxicology | 2009 | 259 |
8 | Zebrafish assays for drug toxicity screening | Expert Opinion on Drug Metabolism and Toxicology | 2006 | 245 |
9 | Species differences in drug transporters and implications for translating preclinical findings to humans | Expert Opinion on Drug Metabolism and Toxicology | 2013 | 239 |
10 | Cytochrome P450 variations in different ethnic populations | Expert Opinion on Drug Metabolism and Toxicology | 2012 | 227 |
11 | Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges | Expert Opinion on Drug Metabolism and Toxicology | 2008 | 225 |
12 | The effect of chronic renal failure on drug metabolism and transport | Expert Opinion on Drug Metabolism and Toxicology | 2008 | 200 |
13 | Neuroinflammation and microglia: considerations and approaches for neurotoxicity assessment | Expert Opinion on Drug Metabolism and Toxicology | 2008 | 200 |
14 | Minimising the potential for metabolic activation in drug discovery | Expert Opinion on Drug Metabolism and Toxicology | 2005 | 198 |
15 | Toxicity of MRI and CT contrast agents | Expert Opinion on Drug Metabolism and Toxicology | 2009 | 195 |
16 | Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs | Expert Opinion on Drug Metabolism and Toxicology | 2009 | 194 |
17 | Glutathione S-transferases: an overview in cancer research | Expert Opinion on Drug Metabolism and Toxicology | 2010 | 190 |
18 | Role of CAR and PXR in xenobiotic sensing and metabolism | Expert Opinion on Drug Metabolism and Toxicology | 2012 | 188 |
19 | Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition | Expert Opinion on Drug Metabolism and Toxicology | 2006 | 187 |
20 | The HepaRG cell line: a uniquein vitrotool for understanding drug metabolism and toxicology in human | Expert Opinion on Drug Metabolism and Toxicology | 2012 | 187 |
21 | The influence of gut microbiota on drug metabolism and toxicity | Expert Opinion on Drug Metabolism and Toxicology | 2016 | 187 |
22 | ABCG2: structure, function and role in drug response | Expert Opinion on Drug Metabolism and Toxicology | 2008 | 182 |
23 | Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia | Expert Opinion on Drug Metabolism and Toxicology | 2008 | 180 |
24 | Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies | Expert Opinion on Drug Metabolism and Toxicology | 2006 | 173 |
25 | The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders | Expert Opinion on Drug Metabolism and Toxicology | 2007 | 173 |
26 | Intestinal efflux transporters and drug absorption | Expert Opinion on Drug Metabolism and Toxicology | 2008 | 173 |
27 | Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction | Expert Opinion on Drug Metabolism and Toxicology | 2011 | 173 |
28 | Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems | Expert Opinion on Drug Metabolism and Toxicology | 2012 | 172 |
29 | The rise of PAMPA | Expert Opinion on Drug Metabolism and Toxicology | 2005 | 171 |
30 | In vitromodels of the human epithelial airway barrier to study the toxic potential of particulate matter | Expert Opinion on Drug Metabolism and Toxicology | 2008 | 171 |
31 | Whole-body physiologically based pharmacokinetic models | Expert Opinion on Drug Metabolism and Toxicology | 2007 | 165 |
32 | The effect of grapefruit juice on drug disposition | Expert Opinion on Drug Metabolism and Toxicology | 2011 | 164 |
33 | Luminogenic cytochrome P450 assays | Expert Opinion on Drug Metabolism and Toxicology | 2006 | 156 |
34 | The role of CYP26 enzymes in retinoic acid clearance | Expert Opinion on Drug Metabolism and Toxicology | 2009 | 154 |
35 | Pharmacokinetic properties and drug interactions of apigenin, a natural flavone | Expert Opinion on Drug Metabolism and Toxicology | 2017 | 153 |
36 | The influence of circadian rhythms on the kinetics of drugs in humans | Expert Opinion on Drug Metabolism and Toxicology | 2008 | 152 |
37 | Competency of different cell models to predict human hepatotoxic drugs | Expert Opinion on Drug Metabolism and Toxicology | 2014 | 152 |
38 | Drug-induced mitochondrial toxicity | Expert Opinion on Drug Metabolism and Toxicology | 2005 | 149 |
39 | Regulation of drug metabolism and disposition during inflammation and infection | Expert Opinion on Drug Metabolism and Toxicology | 2005 | 148 |
40 | The role of aldehyde oxidase in drug metabolism | Expert Opinion on Drug Metabolism and Toxicology | 2012 | 147 |
41 | The role of drug metabolizing enzymes in clearance | Expert Opinion on Drug Metabolism and Toxicology | 2014 | 146 |
42 | Ambroxol in the 21st century: pharmacological and clinical update | Expert Opinion on Drug Metabolism and Toxicology | 2008 | 144 |
43 | In silicoADME-Tox modeling: progress and prospects | Expert Opinion on Drug Metabolism and Toxicology | 2017 | 144 |
44 | Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine | Expert Opinion on Drug Metabolism and Toxicology | 2018 | 144 |
45 | Dexmedetomidine: sedation, analgesia and beyond | Expert Opinion on Drug Metabolism and Toxicology | 2008 | 143 |
46 | Liver tissue engineering in the evaluation of drug safety | Expert Opinion on Drug Metabolism and Toxicology | 2009 | 143 |
47 | Is curcumin bioavailability a problem in humans: lessons from clinical trials | Expert Opinion on Drug Metabolism and Toxicology | 2019 | 140 |
48 | The road map to oral bioavailability: an industrial perspective | Expert Opinion on Drug Metabolism and Toxicology | 2006 | 139 |
49 | ABCG2: the key to chemoresistance in cancer stem cells? | Expert Opinion on Drug Metabolism and Toxicology | 2009 | 138 |
50 | Engineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediation | Expert Opinion on Drug Metabolism and Toxicology | 2010 | 138 |